Alterations in theophylline metabolism during the first year of life

Donna M. Kraus, James H. Fischer, Shirley J. Reitz, Susan A. Kecskes, Tsu F. Yeh, Kristine M. McCulloch, Elizabeth C. Tung, Michael J. Cwik

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Maturational changes in theophylline disposition were evaluated in 52 infants (gestational age, 24 to 40 weeks; postnatal age, 2 to 69 weeks) receiving maintenance theophylline therapy. Theophylline and metabolites were measured in serum and urine at steady state, and the influence of clinical parameters on the maturational changes was analyzed by multiple stepwise linear regression. Theophylline clearance and urine metabolite pattern reached adult values at 55 weeks' postconceptional age. Serum caffeine concentrations greater than 1 µg/ml occurred in infants up to 50 weeks' postconceptional age. Disappearance of serum caffeine concentrations and maturation of theophylline clearance were primarily related (p < 0.001) to development of the demethylation pathway to 3‐methylxanthine. Postconceptional age was the major factor (p < 0.001) explaining the interpatient variability in theophylline clearance (r2 = 0.57), serum caffeine to theophylline ratio (r2 = 0.46), and urinary excretion of theophylline (r2 = 0.51), caffeine (r2 = 0.49), 1,3‐methyluric acid (r2 = 0.32), 1‐methyluric acid (r2 = 0.53), and 3‐methylxanthine (r2 = 0.58). Our findings indicate that postconceptional age rather than postnatal age should be used as a maturational marker during theophylline therapy in infancy. Clinical Pharmacology and Therapeutics (1993) 54, 351–359; doi:

Original languageEnglish
Pages (from-to)351-359
Number of pages9
JournalClinical Pharmacology & Therapeutics
Volume54
Issue number4
DOIs
Publication statusPublished - Jan 1 1993
Externally publishedYes

Fingerprint

Theophylline
Caffeine
Serum
Urine
Acids
Clinical Pharmacology
Gestational Age
Linear Models
Therapeutics
Maintenance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kraus, D. M., Fischer, J. H., Reitz, S. J., Kecskes, S. A., Yeh, T. F., McCulloch, K. M., ... Cwik, M. J. (1993). Alterations in theophylline metabolism during the first year of life. Clinical Pharmacology & Therapeutics, 54(4), 351-359. https://doi.org/10.1038/clpt.1993.160

Alterations in theophylline metabolism during the first year of life. / Kraus, Donna M.; Fischer, James H.; Reitz, Shirley J.; Kecskes, Susan A.; Yeh, Tsu F.; McCulloch, Kristine M.; Tung, Elizabeth C.; Cwik, Michael J.

In: Clinical Pharmacology & Therapeutics, Vol. 54, No. 4, 01.01.1993, p. 351-359.

Research output: Contribution to journalArticle

Kraus, DM, Fischer, JH, Reitz, SJ, Kecskes, SA, Yeh, TF, McCulloch, KM, Tung, EC & Cwik, MJ 1993, 'Alterations in theophylline metabolism during the first year of life', Clinical Pharmacology & Therapeutics, vol. 54, no. 4, pp. 351-359. https://doi.org/10.1038/clpt.1993.160
Kraus, Donna M. ; Fischer, James H. ; Reitz, Shirley J. ; Kecskes, Susan A. ; Yeh, Tsu F. ; McCulloch, Kristine M. ; Tung, Elizabeth C. ; Cwik, Michael J. / Alterations in theophylline metabolism during the first year of life. In: Clinical Pharmacology & Therapeutics. 1993 ; Vol. 54, No. 4. pp. 351-359.
@article{d647a5ed676b4532aa7aa16555bf4bd3,
title = "Alterations in theophylline metabolism during the first year of life",
abstract = "Maturational changes in theophylline disposition were evaluated in 52 infants (gestational age, 24 to 40 weeks; postnatal age, 2 to 69 weeks) receiving maintenance theophylline therapy. Theophylline and metabolites were measured in serum and urine at steady state, and the influence of clinical parameters on the maturational changes was analyzed by multiple stepwise linear regression. Theophylline clearance and urine metabolite pattern reached adult values at 55 weeks' postconceptional age. Serum caffeine concentrations greater than 1 µg/ml occurred in infants up to 50 weeks' postconceptional age. Disappearance of serum caffeine concentrations and maturation of theophylline clearance were primarily related (p < 0.001) to development of the demethylation pathway to 3‐methylxanthine. Postconceptional age was the major factor (p < 0.001) explaining the interpatient variability in theophylline clearance (r2 = 0.57), serum caffeine to theophylline ratio (r2 = 0.46), and urinary excretion of theophylline (r2 = 0.51), caffeine (r2 = 0.49), 1,3‐methyluric acid (r2 = 0.32), 1‐methyluric acid (r2 = 0.53), and 3‐methylxanthine (r2 = 0.58). Our findings indicate that postconceptional age rather than postnatal age should be used as a maturational marker during theophylline therapy in infancy. Clinical Pharmacology and Therapeutics (1993) 54, 351–359; doi:",
author = "Kraus, {Donna M.} and Fischer, {James H.} and Reitz, {Shirley J.} and Kecskes, {Susan A.} and Yeh, {Tsu F.} and McCulloch, {Kristine M.} and Tung, {Elizabeth C.} and Cwik, {Michael J.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1038/clpt.1993.160",
language = "English",
volume = "54",
pages = "351--359",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Alterations in theophylline metabolism during the first year of life

AU - Kraus, Donna M.

AU - Fischer, James H.

AU - Reitz, Shirley J.

AU - Kecskes, Susan A.

AU - Yeh, Tsu F.

AU - McCulloch, Kristine M.

AU - Tung, Elizabeth C.

AU - Cwik, Michael J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Maturational changes in theophylline disposition were evaluated in 52 infants (gestational age, 24 to 40 weeks; postnatal age, 2 to 69 weeks) receiving maintenance theophylline therapy. Theophylline and metabolites were measured in serum and urine at steady state, and the influence of clinical parameters on the maturational changes was analyzed by multiple stepwise linear regression. Theophylline clearance and urine metabolite pattern reached adult values at 55 weeks' postconceptional age. Serum caffeine concentrations greater than 1 µg/ml occurred in infants up to 50 weeks' postconceptional age. Disappearance of serum caffeine concentrations and maturation of theophylline clearance were primarily related (p < 0.001) to development of the demethylation pathway to 3‐methylxanthine. Postconceptional age was the major factor (p < 0.001) explaining the interpatient variability in theophylline clearance (r2 = 0.57), serum caffeine to theophylline ratio (r2 = 0.46), and urinary excretion of theophylline (r2 = 0.51), caffeine (r2 = 0.49), 1,3‐methyluric acid (r2 = 0.32), 1‐methyluric acid (r2 = 0.53), and 3‐methylxanthine (r2 = 0.58). Our findings indicate that postconceptional age rather than postnatal age should be used as a maturational marker during theophylline therapy in infancy. Clinical Pharmacology and Therapeutics (1993) 54, 351–359; doi:

AB - Maturational changes in theophylline disposition were evaluated in 52 infants (gestational age, 24 to 40 weeks; postnatal age, 2 to 69 weeks) receiving maintenance theophylline therapy. Theophylline and metabolites were measured in serum and urine at steady state, and the influence of clinical parameters on the maturational changes was analyzed by multiple stepwise linear regression. Theophylline clearance and urine metabolite pattern reached adult values at 55 weeks' postconceptional age. Serum caffeine concentrations greater than 1 µg/ml occurred in infants up to 50 weeks' postconceptional age. Disappearance of serum caffeine concentrations and maturation of theophylline clearance were primarily related (p < 0.001) to development of the demethylation pathway to 3‐methylxanthine. Postconceptional age was the major factor (p < 0.001) explaining the interpatient variability in theophylline clearance (r2 = 0.57), serum caffeine to theophylline ratio (r2 = 0.46), and urinary excretion of theophylline (r2 = 0.51), caffeine (r2 = 0.49), 1,3‐methyluric acid (r2 = 0.32), 1‐methyluric acid (r2 = 0.53), and 3‐methylxanthine (r2 = 0.58). Our findings indicate that postconceptional age rather than postnatal age should be used as a maturational marker during theophylline therapy in infancy. Clinical Pharmacology and Therapeutics (1993) 54, 351–359; doi:

UR - http://www.scopus.com/inward/record.url?scp=0027490183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027490183&partnerID=8YFLogxK

U2 - 10.1038/clpt.1993.160

DO - 10.1038/clpt.1993.160

M3 - Article

VL - 54

SP - 351

EP - 359

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -